Angiogenesis	O
inhibitors	O
:	O
current	O
strategies	O
and	O
future	O
prospects	O
.	O

Angiogenesis	O
has	O
become	O
an	O
attractive	O
target	O
for	O
drug	O
therapy	O
because	O
of	O
its	O
key	O
role	O
in	O
tumor	B-Cancer
growth	O
.	O

An	O
extensive	O
array	O
of	O
compounds	O
is	O
currently	O
in	O
preclinical	O
development	O
,	O
with	O
many	O
now	O
entering	O
the	O
clinic	O
and	O
/	O
or	O
achieving	O
approval	O
from	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
.	O

Several	O
regulatory	O
and	O
signaling	O
molecules	O
governing	O
angiogenesis	O
are	O
of	O
interest	O
,	O
including	O
growth	O
factors	O
(	O
eg	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
platelet	O
-	O
derived	O
growth	O
factor	O
,	O
fibroblast	O
growth	O
factor	O
,	O
and	O
epidermal	O
growth	O
factor	O
)	O
,	O
receptor	O
tyrosine	O
kinases	O
,	O
and	O
transcription	O
factors	O
such	O
as	O
hypoxia	O
inducible	O
factor	O
,	O
as	O
well	O
as	O
molecules	O
involved	O
in	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
and	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
signaling	O
.	O

Pharmacologic	O
agents	O
have	O
been	O
identified	O
that	O
target	O
these	O
pathways	O
,	O
yet	O
for	O
some	O
agents	O
(	O
notably	O
thalidomide	O
)	O
,	O
an	O
understanding	O
of	O
the	O
specific	O
mechanisms	O
of	O
antitumor	B-Cancer
action	O
has	O
proved	O
elusive	O
.	O

The	O
following	O
review	O
describes	O
key	O
molecular	O
mechanisms	O
and	O
novel	O
therapies	O
that	O
are	O
on	O
the	O
horizon	O
for	O
antiangiogenic	O
tumor	B-Cancer
therapy	O
.	O

